TNGX logo

TANGO THERAPEUTICS INC

TNGXNASDAQ
🏆 #1496 by market capEarnings Nov 2US Equity
$24.45▲ $0.12 (+0.51%)
After hours · at close
🔔
Track TNGX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.5%
7d▼ 4.3%
14d▲ 2.2%
30d▲ 4.7%
ytd▲ 175.7%
1y▲ 189.6%
🏦Market Cap
$3.98B
Small Cap
📈Revenue Growth (YoY)
+48.3%
High Growth
📊Gross Margin
98.3%
High
💵FCF Margin
-268.1%
Thin
⚖️P/S Ratio
73.5x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$24.08 – $24.88
52-Week Range
$6.69 – $34.39
Volume
$3.92B
Avg Volume
$3.94B
Shares Outstanding
162.8M
Next Earnings
Dec 16, 2026

Fundamentals Snapshot

Annual Revenue
$62M
Last Q Revenue
$15M
P/E Ratio
-28.6
P/S Ratio
73.5x
EPS (TTM)
$-0.83
Dividend Yield
0.00%
Dilution (1yr)
+6.9%

Why Investors Own TNGX

  • ✓High-growth profile — revenue up +46.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 7% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TNGX logo

TANGO THERAPEUTICS INC

TNGX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$62M▲ +48.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.3%▼ −3.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$111M▼ −23.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$140M▲ +5.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
116.2M▲ +6.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$79M▲ +$46M YoY
StockOtter · stockotter.space

About TANGO THERAPEUTICS INC

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Ratings

ⓘ
Consensus
Buy
19 analysts
Strong Buy8
Buy9
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

TANGO THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift TNGX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

TANGO THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.